Drug development consultancy Boyds has appointed Kate Owen as Medical Director in its Clinical and Medical Affairs team.
With more than 25 years’ experience as a pharmaceutical physician specialising in early development oncology, haemato-oncology, clinical pharmacology and ATMPs, Kate began her career training as an anaesthetist before working for a CRO. She then spent 16 years at AstraZeneca where she worked as Medicine and Science Director. In 2016, Kate became an independent consultant working with companies around the globe across small molecules, biologics, medical devices and cell…
Prime.io - a london based cell line engineering service CRO company appoints Sir Tony Kouzarides to support long-term strategy for its Next Generation Cell Line Engineering Services.
Tony is a highly cited academic and entrepreneur who co-founded both the Milner Therapeutics Institute and Abcam (NASDAQ: ABCM). As scientific advisor, he will help guide prime.io's scientific strategy and explore new opportunities to raise awareness of the Company’s mission to edit genes and accelerate drug discovery.
Prime.io is a gene editing contract research organization (CRO) that uses AI-designed…
Cambridge, UK, 2nd March 2026: Babraham Research Campus Ltd (BRCL), which is responsible for the development and management of Babraham Research Campus, is delighted to announce the appointment of Dr Rich Ferrie to the role of Chief Executive Officer.
Rich joins Babraham Research Campus from LBIC (London Bioscience Innovation Centre Ltd), a subsidiary of the Royal Veterinary College and key provider of innovation space and support services for early and growth stage life science companies in London’s vibrant Knowledge Quarter. During his tenure as CEO, Rich led the expansion of LBIC…
Prime.io Ltd helps antibody and drug target validation teams to generate high-quality knock-in and knock-out cell models—fast. Powered by our proprietary AI designed CRISPR platform (commercial licence available), we deliver:
• 3x higher knock-in efficiency than conventional spCas9 in pool and single cancer/iPSC cell derived clone
• Up to 97% knock-out efficiency in single cancer/iPSC cell derived clone
• Reduced off-target activity and immunogenicity
• NGS-validated single-cell clones
• Single cell derived edited clone delivery in just 8–12 weeks (if cell doubling rate is around 24…
Building on strong efficacy results, the companies will expand their collaboration to 25,000 patients to identify safety, tolerability, and drug-specific response signals.OXFORD, UK and PORTLAND, ME – 25 February 2026 – Ovation.io, a leading human omics and clinical data company, and PrecisionLife, a precision medicine company transforming how complex chronic diseases are understood and managed, today announced the results of the first phase of their collaboration to develop drug-response biomarkers to quantitively predict the efficacy, safety and tolerability of glucagon-like…
Amsbio offers a comprehensive range of pre-made lentiviral particles for delivering target genes into most types of dividing and non-dividing mammalian cells in vitro and in vivo.
Lentiviral particles provide long-term, stable expression of genes, making them ideal for stable cell line engineering, CRISPR applications, and therapeutic gene transfer.
Key advantages of Amsbio lentiviral particles include their ease of use, high titer, purity, and safety features. These pre-made lentiviral particles come ready-to-use, eliminating the need for transfection reagents and saving…
The pioneering purpose-built life science facility opens in March 2026
Glasgow, February, 2026
Located within the Glasgow Riverside Innovation District (GRID), the highly anticipated Health Innovation Hub (HiH) has secured Panthera as a new tenant ahead of its official opening next month. The announcement further strengthens the Hub’s growing community of healthcare innovators and highlights its role in supporting collaboration, growth and clinical excellence.
Panthera, which recruits patients and runs clinical trials for pharmaceutical and biotech companies and the seven largest Contract…
LONDON, UK and COPENHAGEN, Denmark – February 24, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led the search for Hans T. Schambye, MD, PhD for his appointment to the Board of Directors at BOOST Pharma (“BOOST”), and is now pleased to announce his transition to Chief Executive Officer (CEO). BOOST Pharma is a clinical‑stage biopharmaceutical company developing novel, first‑in‑class off-the-shelf cell therapies for rare, debilitating pediatric skeletal diseases. The Company’s lead…
22,000 sq ft of space in Wilton Centre’s Technical Development Area (TDA) has been leased to growing companies breathing new life into used metals and accelerating Teesside’s net zero ambitions.
An iconic research space in Europe’s R&D landscape, Wilton Centre near Redcar is home to 60 businesses, with 12 of these operating in its TDA – a 100,000 sq ft complex of four specialised, industrial buildings that can accommodate chemical pilot plants, development rigs, machine testing and light industrial activity.
Recently moving into the TDA is DEScycle, a deep tech company building the next…
In pharma, the question isn’t whether AI can be used — it’s how to use it responsibly, without putting regulatory submissions, scientific credibility, or patient safety at risk.
In our latest white paper, we look at how pharma library and medical information teams are building trust in AI, including:
- Understanding when outputs can be trusted and when human review is non-negotiable
- Knowing what makes AI outputs defensible under regulatory and scientific review
- Defining guardrails before adoptions scales
👉 Download the white paper to see how teams are approaching AI responsibly: https://…